EIDD-036
From The Right Wiki
| File:EIDD-036.svg | |
| Clinical data | |
|---|---|
| Other names | EPRX-036; Progesterone 20-oxime; P4-20-O; Pregn-4-ene-3,20-dione 20-oxime; 20-(Hydroxyimino)pregn-4-en-3-one |
| Drug class | Neurosteroid |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C21H31NO2 |
| Molar mass | 329.484 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
EIDD-036, also known as EPRX-036, as well as progesterone 20-oxime (P4-20-O) or 20-(hydroxyimino)pregn-4-en-3-one, is a synthetic, water-soluble analogue of progesterone, a neurosteroid, and the active metabolite of EIDD-1723 (EPRX-01723), a medication developed for the potential treatment of traumatic brain injury.[1][2][3][4]
See also
- List of neurosteroids § Inhibitory > Synthetic > Pregnanes
- List of progestogen esters § Oximes of progesterone derivatives
References
- ↑ Wali B, Sayeed I, Guthrie DB, Natchus MG, Turan N, Liotta DC, Stein DG (October 2016). "Evaluating the neurotherapeutic potential of a water-soluble progesterone analog after traumatic brain injury in rats". Neuropharmacology. 109: 148–158. doi:10.1016/j.neuropharm.2016.05.017. PMID 27267687. S2CID 19906601.
- ↑ Guthrie, D. B., Lockwood, M. A., Natchus, M. G., Liotta, D. C., Stein, D. G., & Sayeed, I. (2017). U.S. Patent No. 9,802,978. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9802978B2/en
- ↑ MacNevin CJ, Atif F, Sayeed I, Stein DG, Liotta DC (October 2009). "Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury". J. Med. Chem. 52 (19): 6012–23. doi:10.1021/jm900712n. PMID 19791804.
- ↑ Guthrie DB, Stein DG, Liotta DC, Lockwood MA, Sayeed I, Atif F, Arrendale RF, Reddy GP, Evers TJ, Marengo JR, Howard RB, Culver DG, Natchus MG (May 2012). "Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury". ACS Med Chem Lett. 3 (5): 362–6. doi:10.1021/ml200303r. PMC 4025794. PMID 24900479.
